Skip to main content

Table 1 Measurement of the levels of blood glucose

From: Beneficial effect of TNF-α inhibition on diabetic peripheral neuropathy

Time

0 week

4 weeks

CTL

6.26 ± 1.04

6.45 ± 0.92

DPN

19.58 ± 3.37a

20.78 ± 4.10

DPN + T1

20.95 ± 3.86a

20.58 ± 3.71

DPN + T2

19.95 ± 3.66a

20.53 ± 6.11

  1. Note: Animals were injected subcutaneously with rhTNFR:Fc in rhTNFR:Fc-treated groups or with physiological buffered saline (PBS) as a vehicle in normal control (CTL) and in DPN groups twice per week for 4 weeks. Unit of blood glucose: mmol/L. DPN, diabetic peripheral neuropathy; T1, 0.4 mg/kg rhTNFR:Fc treatment; T2, 4 mg/kg rhTNFR:Fc treatment.
  2. aCompared with group of CTL, P <0.05 (n = 12).